Strategic partnerships Discovery Life Sciences has active collaborations with Biocartis and MindPeak to deliver end-to-end precision oncology solutions and AI-enabled pathology insights, signaling strong potential for co-development deals, AI-assisted biomarker workflows, and expanded service use in pharmaceutical pipelines.

Expanded genomic offering Recent launch of Luminos Comprehensive 164-gene CGP panel and in-house validation under IVDR at Kassel indicates a scalable genomics service line suitable for pharma partners seeking comprehensive tumor profiling and diagnostic-grade companion test development.

Legacy and access programs The Discovery Legacy Program provides discounted access to curated older biospecimens, creating opportunities to upsell tiered biospecimen access, retrospective studies, and cost-optimized trial designs for sponsors with budget-sensitive research.

Digital pathology AI Partnership with MindPeak for AI-enabled digital image analysis in IHC and mIF across global trials demonstrates readiness to offer enhanced imaging analytics, enabling better biomarker discovery and more robust assay validation for sponsors.

Global clinical trial readiness Global biospecimen and specialty lab capabilities, combined with cross-functional services (molecular pathology, genomics, proteomics, flow cytometry) position Discovery Life Sciences as a one-stop partner for end-to-end clinical trial support, appealing to sponsors seeking streamlined procurement and integrated analytics.